Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Richard Vosser
JPM
Richard Vosser
J.P. Morgan
Wall Street Analyst
★★★☆☆
#1358
on 13Foresight · ranked by our own returns
55%
Success Rate
+6.7%
Average Return
6 of 11 calls profitable · -15.0% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 55% of Richard Vosser's ratings turned a profit when each position was held for 1 year — averaging +6.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

115 Buy 57 Hold 18 Sell
Richard's Stock Coverage 33 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
GB:AZN
AstraZeneca
 Jun 09, 2026 BUY Strong Buy
+11.9% avg upside
26 analysts
$16000.00
21.27% Upside
 ·
GB:0QIU
Novo Nordisk
 Jun 08, 2026 HOLD Hold
+45.6% avg upside
28 analysts
$250.00
13.24% Downside
 ·
DE:MRK
Merck KGaA
 Jun 01, 2026 BUY Buy
+2.1% avg upside
32 analysts
$150.00
12.96% Upside
 ·
DE:BAYN
Bayer
 May 12, 2026 BUY Strong Buy
+34.9% avg upside
28 analysts
$50.00
35.41% Upside
 ·
FR:SAN
Sanofi
 May 05, 2026 HOLD Strong Buy
+33.0% avg upside
30 analysts
$95.00
29.53% Upside
 ·
CH:NOVN
Novartis AG
 May 05, 2026 BUY Buy
-10.2% avg upside
30 analysts
$135.00
13.76% Upside
 ·
CH:ROP
Roche Holding AG
 May 01, 2026 HOLD Buy
+3.2% avg upside
23 analysts
$325.00
1.39% Upside
 ·
DE:SRT3
Sartorius
 Apr 23, 2026 BUY Buy
+26.8% avg upside
17 analysts
$295.00
36.85% Upside
 ·
FR:DIM
Sartorius Stedim Biotech
 Apr 23, 2026 BUY Strong Buy
+51.3% avg upside
10 analysts
$260.00
58.53% Upside
 ·
FR:IPN
Ipsen
 Mar 27, 2026 HOLD Buy
-21.4% avg upside
17 analysts
$130.00
16.53% Downside
 ·
GB:0QW0
arGEN X
 Mar 05, 2026 BUY Strong Buy
-23.2% avg upside
24 analysts
$950.00
23.49% Upside
 ·
GB:GSK
GlaxoSmithKline
 Dec 23, 2025 SELL Hold
-3.3% avg upside
25 analysts
 — ·
ARGX
Argenx Se
 Dec 08, 2025 BUY Strong Buy
-15.8% avg upside
46 analysts
$1100.00
26.65% Upside
 -2.0%
CH:MOLN
Molecular Partners AG
 Dec 08, 2025 HOLD Strong Buy
+559.3% avg upside
5 analysts
$3.00
3.21% Downside
 ·
GB:0NZT
UCB SA
 Dec 08, 2025 BUY Buy
-13.5% avg upside
19 analysts
$300.00
20.33% Upside
 ·
NVO
Novo Nordisk
 Nov 24, 2025 BUY Buy
+168.1% avg upside
26 analysts
 — +0.3%
NVS
Novartis
 Nov 20, 2025 HOLD Hold
-7.8% avg upside
24 analysts
 — +25.1%
MOLN
Molecular Partners
 Sep 03, 2025 HOLD Strong Buy
+161.4% avg upside
7 analysts
$4.00
2.57% Upside
 +12.9%
DE:SRT
Sartorius
 Jul 22, 2025 BUY Buy
+131.6% avg upside
4 analysts
$260.00
50.93% Upside
 ·
FR:EAPI
Euroapi SA
 Dec 03, 2024 HOLD Buy
+539.1% avg upside
5 analysts
$3.50
181.43% Upside
 ·
CH:LONN
Lonza Group Ltd
 Dec 03, 2024 BUY Strong Buy
+27.2% avg upside
19 analysts
$650.00
32.75% Upside
 ·
BAYRY
Bayer
 Dec 05, 2023 HOLD Buy
+293.3% avg upside
9 analysts
$39.48
273.93% Upside
 -39.6%
IT:REC
Recordati Industria Chimica e Farmaceutica SPA
 Jan 03, 2023 BUY Hold
-9.8% avg upside
6 analysts
$43.05
14.93% Downside
 ·
GB:HIK
Hikma Pharmaceuticals
 Sep 27, 2021 BUY Buy
+63.8% avg upside
7 analysts
$3000.00
106.58% Upside
 ·
NKE
Nike
 Mar 18, 2021 BUY Buy
+74.8% avg upside
48 analysts
$176.00
289.55% Upside
 -7.6%
RHHBY
Roche Holding
 Dec 21, 2020 BUY Buy
+0.0% avg upside
14 analysts
 — +23.0%
UCBJY
UCB SA
 Jul 28, 2020 BUY Strong Buy
+11.8% avg upside
2 analysts
$144.00
1.23% Upside
 -16.9%
LKFT
Lakefront Biotherapeutics
 Mar 02, 2020 HOLD Hold
+272.9% avg upside
24 analysts
$200.00
608.70% Upside
 ·
NL:LKFT
Galapagos
 Jan 06, 2020 HOLD Sell
+112.3% avg upside
16 analysts
$185.00
647.20% Upside
 ·
GMAB
Genmab
 Jan 02, 2019 HOLD Buy
+38.2% avg upside
26 analysts
 — +42.9%
GB:0MGB
Genmab A/S
 Jan 02, 2019 HOLD Buy
+32.3% avg upside
22 analysts
$1150.00
28.84% Downside
 ·
SNY
Sanofi
 Apr 11, 2017 HOLD Strong Buy
+74.9% avg upside
20 analysts
 — -6.8%
GRFS
Grifols SA
 Jan 04, 2017 BUY Buy
+242.8% avg upside
12 analysts
$22.00
195.76% Upside
 +43.0%
🔒 28 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Richard Vosser — Frequently Asked Questions
How accurate are Richard Vosser's stock ratings?
Based on the calls 13Foresight could measure, about 55% of Richard's ratings were profitable over a one-year hold, with an average return of +6.7% per rating, or -15.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Richard ranked on 13Foresight?
Richard Vosser is currently ranked #1358 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Richard cover?
Richard most recently has ratings on GB:AZN, GB:0QIU, DE:MRK, DE:BAYN, FR:SAN, CH:NOVN, CH:ROP, DE:SRT3, FR:DIM, FR:IPN, GB:0QW0, GB:GSK and 21 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.